{"id":10463,"date":"2025-10-19T20:34:43","date_gmt":"2025-10-20T03:34:43","guid":{"rendered":"https:\/\/www.telemedical.com\/wordpress\/?page_id=10463"},"modified":"2026-02-11T22:01:44","modified_gmt":"2026-02-12T06:01:44","slug":"treatments-in-the-development-pipeline","status":"publish","type":"page","link":"https:\/\/www.telemedical.com\/wordpress\/home\/alzheimers\/treatments-in-the-development-pipeline\/","title":{"rendered":"Treatments in development"},"content":{"rendered":"\n
\n
\n
\n
\n
\n
\n
Small Molecule Drug<\/strong><\/td>Mechanism of Action<\/strong><\/td>Study Phase<\/td><\/tr>
AR1001<\/a><\/td>Nuerotransmitter Receptors<\/td>3<\/td><\/tr>
Buntanetap<\/a><\/td>Proteostasis<\/td>3<\/td><\/tr>
Mastinib<\/a><\/td>Inflammation\/Immunity<\/td>3<\/td><\/tr>
Metformin<\/td>Metabolism\/Bioenergetics<\/td>3<\/td><\/tr>
Niolimib<\/a><\/td>Proteostasis<\/td>3<\/td><\/tr>
PMO12<\/a> – herbal formula<\/a><\/td>Neurogenesis<\/td>3<\/td><\/tr>
Simufilam ( failed phase 3 studies)<\/td>Epigenetic regulator<\/td>3<\/td><\/tr>
Tricaprilin<\/a><\/td>Metabolism\/Bioenergetics<\/td>3<\/td><\/tr>
Valiltramiprosate<\/a> <\/td>prevents oligomerization of Amyloid Beta<\/td>3<\/td><\/tr>
Wujia Yitzhi<\/a><\/td>inflammation\/Immunity<\/td>3<\/td><\/tr>
<\/td>ACAT 1 inhibitors<\/a><\/td>3<\/td><\/tr>
\u03b2\u2010Caryophyllene<\/a><\/td>Ameliorates STZ\u2010Induced Alzheimer’s Disease\u2010Like Conditions in Rats via Modulation of Brain\u2010Derived Neurotrophic Factor, Synaptic Plasticity, and Neuroinflammation – Rathod – 2025 <\/a><\/td><\/td><\/tr>
Damona Pharmaceuticals<\/a> – DPX- 101<\/td>(PAM) that targets the \u03b15-GABA-A receptor<\/td>3<\/td><\/tr>
Biological Drug<\/strong><\/td><\/td><\/td><\/tr>
Trontinemab ( Brain Shuttled gantenerumab ) – Roche<\/td>anti amyloid + anti Transferrin Receptor FCGamma2\/1<\/td><\/td><\/tr>
Lecanemab- <\/td>anti amyloid antibody<\/td><\/td><\/tr>
Semaglutide<\/td>anti brain inflammation<\/td><\/td><\/tr>
Gonadorelin<\/td>Growth factor\/hormone<\/td><\/td><\/tr>
Donanemab – <\/td>anti amyloid antibody<\/td><\/td><\/tr>

E2814<\/td>		Tau<\/td><\/td><\/tr>

Gantenerumab <\/td>		anti amyloid antibody<\/td><\/td><\/tr>
Terlomotide is a fragment derived from the human telomerase reverse transcriptase (hTERT) enzyme, specifically a 16\u2013amino acid sequence (hTERT 611\u2013626).<\/td>Amyloid<\/td><\/td><\/tr>
Remternetug <\/td>anti-amyloid antibody developed by Eli Lilly<\/td><\/td><\/tr>
<\/td><\/td><\/td><\/tr>
<\/td><\/td><\/td><\/tr>
Solanezumab <\/td>selectively targets and binds to soluble monomeric forms of amyloid-beta (A\u03b2) peptides in the brain – from Eli Lilly<\/td><\/td><\/tr>
Posdinemab<\/td>anti -Tau antibody<\/td><\/td><\/tr>
Bepranemab<\/td>anti- Tau antibody<\/td><\/td><\/tr>
E2814<\/td>anti -Tau Antibody
<\/td>		<\/td><\/tr>
BMS-986446<\/td>Anti-Tau antibody<\/td><\/td><\/tr>
APmAb005<\/td>Anti -Tau Antibody<\/td><\/td><\/tr>
MK2214<\/td>
Anti -Tau Antibody<\/td>		<\/td><\/tr>
VY-Tau01<\/td>
Anti -Tau Antibody<\/td>		<\/td><\/tr>
ADEL-Y01<\/td>
Anti -Tau Antibody<\/td>		<\/td><\/tr>
anti-PDL1 antibody https:\/\/clinicaltrials.gov\/study\/NCT05551741<\/a><\/td>Activation of Anti- Senescent Microglial Activity or
Elimination of Senescent CD8 T cells<\/td>		1<\/td><\/tr>
Cellular Therapy<\/strong><\/td><\/td><\/td><\/tr>
Autologous NK cell expansion and activation by NKGen Biotech<\/a><\/td>Removal of pathogenic senescent cells<\/td><\/td><\/tr>
Stem Cells – Various Types<\/td>Regeneration or replacement of pathogenic cells<\/td><\/td><\/tr>
Reprogrammed T cells can eliminate senescent cells<\/a><\/td>Removal of pathogenic senescent cells<\/td><\/td><\/tr>
CAR-T or NK Cell therapy<\/a><\/td>Removal of pathogenic senescent cells<\/td><\/td><\/tr>
CAR-T with anti uPAR – Cold Spring Harbor\/Memorial Kettering Cancer Institute<\/td>Removal of pathogenic senescent cells<\/td><\/td><\/tr>
CAR-T with anti- KLRG1 <\/a>= <\/a>Anti Senescent CD<\/a>8 TCell Therapy from Ortega Neuro Tx<\/td>Removal of pathogenic senescent cells<\/td><\/td><\/tr>
Genetically engineered microglia with trans skull brain injection<\/td>Regeneration or replacement of pathogenic cells<\/td><\/td><\/tr>
<\/td><\/td><\/td><\/tr>
Gene Therapy<\/strong> – viral vector<\/td><\/td><\/td><\/tr>
KCTD20 gene inactivation in glutamate excitatory neurons<\/a><\/td><\/td><\/td><\/tr>
Intracisternal CSF injection of AAV vectors with ApoE2 christchurch and anti APOE4 miRNA<\/td><\/td><\/td><\/tr>
EV therapy<\/strong><\/td><\/td><\/td><\/tr>
small Extracellular vesicles with protein exerkines, miRNA, AAV vectors, and\/or circRNA<\/td><\/td><\/td><\/tr>
<\/td><\/td><\/td><\/tr>
40 Hz Ultrasound<\/strong> and Light<\/td><\/td><\/td><\/tr>
Cognito<\/a>‘s Device<\/td><\/td><\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div>\n<\/div>\n\n\n\n
\n
<\/div>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n

Reducing pathogenic-senescent- memory CD8 T cells <\/a>with T cell aPharesis or Senolytics ( drug, biologic, CAR-T, Activated NK, CAR-NK, EV, or gene therapy)<\/p>\n\n\n\n

Biologics and small Drug Molecule<\/a><\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n

Each of the 11 grants is for approximately $1 million. The new Part the Cloud grant awardees are:<\/p>\n\n\n\n

Translational Research Grant Program<\/p>\n\n\n\n

    \n
  • Glenn Larsen, Ph.D., Aquinnah Pharmaceuticals, Inc. Tauopathy Therapeutic AQV-8741: A Phase I Study.<\/li>\n\n\n\n
  • Terry Goldberg, Ph.D., Research Foundation for Mental Hygiene, Inc. at New York State Psychiatric Institute. Vortioxetine to improve synaptic connectivity.<\/li>\n\n\n\n
  • Luis Oskar Soto-Rojas, Ph.D., National Autonomous University of Mexico. Creatine-Augmented Exercise for Neuroprotection in Early AD patients.<\/li>\n\n\n\n
  • Timothy Siegert, Ph.D., Allyx Therapeutics, Inc. A Phase 2A Trial of ALX-001 (BMS-984923).<\/li>\n\n\n\n
  • Alireza Faridar, M.D., The Methodist Hospital Research Institute. IL-2 plus GLP-1 RA Combination Therapy to Target Inflammation in AD.<\/li>\n<\/ul>\n\n\n\n

    Gene Targeting Challenge<\/p>\n\n\n\n

      \n
    • Rita Balice-Gordon, Ph.D., Muna Therapeutics. Small Molecule TREM2 Agonism: Phase 1 and Observational Studies in Early AD.<\/li>\n<\/ul>\n\n\n\n

      Enable the Molecule Program<\/p>\n\n\n\n

        \n
      • Evan Lebois, Ph.D., Violet Therapeutics, Inc. Novel small molecule EPHB3 inhibitors to prevent AD synapse loss.<\/li>\n\n\n\n
      • Anindya Bhattacharya, Ph.D., Switch Therapeutics, Inc. Targeting MAPT knockdown by a unique siRNA platform to treat Alzheimer’s.<\/li>\n\n\n\n
      • Can Zhang, M.D., Ph.D., and Changning Wang, Ph.D., Massachusetts General Hospital. Discovery of novel epigenetic inhibitors for Alzheimer\u2019s disease.<\/li>\n\n\n\n
      • Mark Heiman, Ph.D., and Adrian Noriega, M.D., Ph.D., Pramana Pharmaceuticals Inc. IND readiness for PRM914 a Novel Oral Gut-Brain treatment for Alzheimer’s.<\/li>\n\n\n\n
      • Judith Kelleher-Andersson, Ph.D., Neuronascent, Inc. Aged CCD Field Trial for Go-no-go Decision of NNI-362 Ph2 POC Trial.<\/li>\n<\/ul>\n\n\n\n

        <\/p>\n","protected":false},"excerpt":{"rendered":"

        Small Molecule Drug Mechanism of Action Study Phase AR1001 Nuerotransmitter Receptors 3 Buntanetap Proteostasis 3 Mastinib Inflammation\/Immunity 3 Metformin Metabolism\/Bioenergetics 3 Niolimib Proteostasis 3 PMO12 – herbal formula Neurogenesis 3 Simufilam ( failed phase 3 studies) Epigenetic regulator 3 Tricaprilin Metabolism\/Bioenergetics 3 Valiltramiprosate prevents oligomerization of Amyloid Beta 3 Wujia Yitzhi inflammation\/Immunity 3 ACAT 1 […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":7860,"menu_order":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-10463","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.telemedical.com\/wordpress\/wp-json\/wp\/v2\/pages\/10463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.telemedical.com\/wordpress\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.telemedical.com\/wordpress\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.telemedical.com\/wordpress\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.telemedical.com\/wordpress\/wp-json\/wp\/v2\/comments?post=10463"}],"version-history":[{"count":35,"href":"https:\/\/www.telemedical.com\/wordpress\/wp-json\/wp\/v2\/pages\/10463\/revisions"}],"predecessor-version":[{"id":11428,"href":"https:\/\/www.telemedical.com\/wordpress\/wp-json\/wp\/v2\/pages\/10463\/revisions\/11428"}],"up":[{"embeddable":true,"href":"https:\/\/www.telemedical.com\/wordpress\/wp-json\/wp\/v2\/pages\/7860"}],"wp:attachment":[{"href":"https:\/\/www.telemedical.com\/wordpress\/wp-json\/wp\/v2\/media?parent=10463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}